AAPL
Apple Inc.
AAPL has the edge over DBD overall, supported by stronger fundamentals and lower modeled downside.
DBD
Diebold Nixdorf, Incorporated
DBD offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
AAPL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
AAPL's revenue, profitability, cash flow and balance sheet are all currently healthy.
DBD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
DBD's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
AAPL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 26x | $230 | -35% |
| Fair | 31x | $279 | -21% |
| Expensive | 37x | $328 | -7.5% |
| Forward | 38x | $355 | — |
| Current | 40x | $355 | — |
Historical ranges are pointers, not guarantees.
AAPL has the edge over DBD in the historical PE scenario, which offers more potential upside but is not a forecast.
DBD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.7x | $1.54 | -97% |
| Forward | 9.8x | $54.75 | — |
| Fair | 22x | $44.94 | -18% |
| Current | 26x | $54.75 | — |
| Expensive | 32x | $67.83 | +24% |
Historical ranges are pointers, not guarantees.
DBD's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 9.8x next year's earnings.
AAPL Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Weakening | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AAPL, but weaker profitability.
DBD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect DBD's earnings to grow and its profitability to improve, with its revenue holding steady.
AAPL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.28 | +3.3% |
| Q3 2026 | $8.98 | +20% |
| Q2 2026 | $8.71 | +32% |
| Q1 2026 | $8.26 | +29% |
| Q4 2025 | $7.90 | +25% |
| Q3 2025 | $7.46 | +23% |
| Q2 2025 | $6.59 | +0.2% |
| Q1 2025 | $6.42 | -0.3% |
| Q4 2024 | $6.30 | -2% |
AAPL has the edge over DBD on earnings, with more consistent year-over-year improvement.
DBD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.56 | +166% |
| Q3 2026 | $2.09 | +53% |
| Q2 2026 | $3.01 | +$3.35 |
| Q1 2026 | $2.90 | +$3.17 |
| Q4 2025 | $2.54 | +$2.98 |
| Q3 2025 | $1.37 | +$1.37 |
| Q2 2025 | -$0.34 | -101% |
| Q1 2025 | -$0.27 | -101% |
| Q4 2024 | -$0.44 | -101% |
DBD's earnings per share have fallen from their peak: $2.09 over the past year, against $57.03 in mid-2024.
AAPL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $114.5B | +12% |
| Q2 2026 | $109.4B | +16% |
| Q1 2026 | $111.2B | +17% |
| Q4 2025 | $143.8B | +16% |
| Q3 2025 | $102.5B | +7.9% |
| Q2 2025 | $94B | +9.6% |
| Q1 2025 | $95.4B | +5.1% |
| Q4 2024 | $124.3B | +4% |
AAPL has the edge over DBD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | -0.5 points |
| Q2 2026 | 33% | +2.6 points |
| Q1 2026 | 32% | +1.3 points |
| Q4 2025 | 35% | +0.9 points |
| Q3 2025 | 32% | +0.5 points |
| Q2 2025 | 30% | +0.4 points |
| Q1 2025 | 31% | +0.3 points |
| Q4 2024 | 34% | +0.7 points |
AAPL has the edge over DBD on profitability, with a higher operating margin.
DBD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $994.3M | +5.2% |
| Q2 2026 | $930.8M | +1.7% |
| Q1 2026 | $891.8M | +6% |
| Q4 2025 | $1.1B | +12% |
| Q3 2025 | $945.2M | +2% |
| Q2 2025 | $915.2M | -2.6% |
| Q1 2025 | $841.1M | -6.1% |
| Q4 2024 | $988.9M | -4.6% |
DBD's revenue has grown year over year for five quarters in a row: $994M last quarter, up 5.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.9% | -3.9 points |
| Q2 2026 | 6.2% | 0 points |
| Q1 2026 | 3.7% | +0.1 points |
| Q4 2025 | 7.5% | +3.3 points |
| Q3 2025 | 7.8% | +2.8 points |
| Q2 2025 | 6.1% | -1.4 points |
| Q1 2025 | 3.5% | +0.9 points |
| Q4 2024 | 4.2% | -1.2 points |
DBD's operating margin was 3.9% last quarter, down 3.9 points from the same quarter a year ago.
AAPL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.9B | -2.4% |
| Q2 2026 | $31.9B | +31% |
| Q1 2026 | $26.7B | +28% |
| Q4 2025 | $51.6B | +91% |
| Q3 2025 | $26.5B | +11% |
| Q2 2025 | $24.4B | -8.6% |
| Q1 2025 | $20.9B | +0.9% |
| Q4 2024 | $27B | -28% |
AAPL's free cash flow has been positive every quarter for seven years: $136B over the past year, up 38% from the year before.
DBD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.4M | -227% |
| Q2 2026 | -$13.6M | -145% |
| Q1 2026 | $31.7M | +102% |
| Q4 2025 | $217.5M | +11% |
| Q3 2025 | $37.4M | +$52.9M |
| Q2 2025 | $30.1M | +$38.1M |
| Q1 2025 | $15.7M | +$39.2M |
| Q4 2024 | $196.2M | +26% |
DBD has the edge over AAPL on cash flow, with more consistent year-over-year improvement.
AAPL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +5.6M shares |
| 1 year | -1.9% | -284M shares |
| 3 years | -6.9% | -1.1B shares |
| 5 years | -13% | -2.1B shares |
| Available history | -17% | -3.1B shares |
AAPL has 14.7B diluted shares, down 1.9% from a year ago, with $86.4B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $24.3B |
| Q2 2026 | $25.1B |
| Q1 2026 | $12.3B |
| Q4 2025 | $24.7B |
| Q3 2025 | $20.1B |
| Q2 2025 | $21.1B |
| Q1 2025 | $25.9B |
| Q4 2024 | $23.6B |
AAPL spent $86.4B buying back its own shares over the past year, down 4.8% from the year before.
DBD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -700K shares |
| 1 year | -6.5% | -2.4M shares |
| 3 years | -7.9% | -3M shares |
| 5 years | -56% | -43.7M shares |
| Available history | -55% | -42.2M shares |
DBD has the edge over AAPL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $33.9M |
| Q2 2026 | $60.6M |
| Q1 2026 | $60.4M |
| Q4 2025 | $51.1M |
| Q3 2025 | $39.9M |
| Q2 2025 | $30.1M |
| Q1 2025 | $9.6M |
| Q4 2024 | $2.3M |
DBD spent $206M buying back its own shares over the past year, up 152% from the year before.
AAPL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.3x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.5x | Very low |
AAPL has the edge over DBD on leverage, with a lower net debt burden relative to earnings.
DBD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.5x | Moderate |
| Q1 2025 | 2.7x | Moderate |
| Q4 2024 | 2.8x | Moderate |
DBD's net debt is about 2.3 years of its operating earnings (EBITDA), about the same as a year ago.
AAPL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.1 | Neutral |
| Stochastic | 85.0 | Overbought |
AAPL's weekly RSI is 68 (neutral) and its Stochastic is 85 (overbought).
DBD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 11.4 | Oversold |
DBD's weekly RSI is 35 (neutral) and its Stochastic is 11 (oversold).
AAPL PE vs Technology Sector
| Metric | AAPL | Sector median | Relative |
|---|---|---|---|
| PE | 40x | 28x | 42% above |
| PE % | 96 | 35 | 61 pts above |
AAPL is trading at 40x earnings, a 42% premium to the Technology sector's median of 28x.
DBD PE vs Technology Sector
| Metric | DBD | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 28x | 6% below |
| PE % | 61 | 25 | 36 pts above |
DBD has the edge over AAPL on valuation relative to its sector.
AAPL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $343.1 | 3.4% above |
| 20 week MA | $329.0 | 7.9% above |
| 50 week MA | $295.6 | 20% above |
| 100 week MA | $262.4 | 35% above |
| 200 week MA | $226.3 | 57% above |
AAPL has stronger trend alignment. AAPL is above 5 of 5 weekly averages versus DBD above 0 of 4.
DBD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.8 | 11% below |
| 20 week MA | $69.7 | 21% below |
| 50 week MA | $73.3 | 25% below |
| 100 week MA | $62.4 | 12% below |
DBD is in a downtrend: it's below all four of its weekly moving averages, and 12% below its 100-week average.
AAPL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $72.5 | $132.0 | +82% |
| 2021 | $132.0 | $176.3 | +34% |
| 2022 | $176.3 | $131.9 | -25% |
| 2023 | $131.9 | $192.5 | +46% |
| 2024 | $192.5 | $255.6 | +33% |
| 2025 | $255.6 | $273.4 | +7% |
| 2026 YTD | $273.4 | $354.9 | +30% |
AAPL has the edge over DBD on returns for 2026, with the stronger performance.
DBD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $20.1 | $29.0 | +44% |
| 2024 | $29.0 | $42.9 | +48% |
| 2025 | $42.9 | $69.3 | +61% |
| 2026 YTD | $69.3 | $54.8 | -21% |
DBD has finished every year since 2023 higher, and it's down 21% so far in 2026.